Advanced Search
MyIDEAS: Login to follow this JEL code

Research classified by Journal of Economic Literature (JEL) codes


Top JEL
/ L: Industrial Organization
/ / L6: Industry Studies: Manufacturing
/ / / L65: Chemicals; Rubber; Drugs; Biotechnology
This topic is covered by the following reading lists:
  1. Industrial Sociology (FCT-UNL)

Most recent items first, undated at the end.
  • 2014 Internationale Expansion in der pharmazeutischen Industrie Österreichs
    by Christian Zeller & Andreas Hametner & Koen Smet & Markus Seiwald
  • 2014 Porto Marghera and the Industrial Ecology Challenge: Why it did not become an Eco-Industrial Park
    by Mannino, Ilda & Ninka, Eniel & Turvani, Margherita
  • 2014 Price Regulation and Parallel Imports of Pharmaceuticals
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
  • 2014 Patents and the Global Diffusion of New Drugs
    by Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman
  • 2014 Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
    by Keith M. Drake & Martha A. Starr & Thomas McGuire
  • 2014 Defacto and Deeded Intellectual Property: Knowledge-Driven Co-Evolution of Firm Collaboration Boundaries and IPR Strategy
    by Lynne G. Zucker & Michael R. Darby
  • 2014 Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
    by Rena M. Conti & Ernst R. Berndt
  • 2014 Gravity and Extended Gravity: Using Moment Inequalities to Estimate a Model of Export Entry
    by Eduardo Morales & Gloria Sheu & Andrés Zahler
  • 2014 Direct to Consumer Advertising of Pharmaceutical Drugs: Information and Persuasion
    by Talia Bar & Dean R. Lillard
  • 2014 Price Regulation and Parallel Imports of Pharmaceuticals
    by Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune
  • 2014 Reforming the Swedish pharmaceuticals market – consequences for costs per defined daily dose
    by Bergman, Mats & Granlund, David & Rudholm, Niklas
  • 2014 On compensation schemes for data sharing within the european REACH legislation
    by Sylvain Béal & Marc Deschamps
  • 2014 Patents and the Global Diffusion of New Drugs
    by Cockburn, Iain M & Lanjouw, Jean O & Schankerman, Mark
  • 2014 Carestía e inflación: qué esperar de la política agrícola y los gravámenes a la tierra y el carbono
    by Carlos Gustavo Cano
  • 2014 Sources of Productivity Spillovers: Panel Data Evidence from China
    by Badi H. Baltagi & Peter Egger & Michaela Kesina
  • 2014 The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry
    by Tannista Banerjee & Ralph Siebert
  • 2014 Patents and the Global Diffusion of New Drugs
    by Iain Cockburn & Jean O. Lanjouw & Mark Schankerman
  • 2014 Entry Threats and Pricing in the Generic Drug Industry
    by Steven Tenn & Brett W. Wendling
  • 2014 Montedison. Il dinosauro nel MEC
    by Paolo Sylos Labini
  • 2014 Innovation and Market Structure in Pharmaceuticals: An Econometric Analysis on Simulated Data
    by Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni
  • 2014 Pharmaceutical economics
    by William S. Comanor & Stuart O. Schweitzer
  • 2014 R&D portfolios and pharmaceutical licensing
    by Nishimura, Junichi & Okada, Yosuke
  • 2014 Scientific knowledge dynamics and relatedness in biotech cities
    by Boschma, Ron & Heimeriks, Gaston & Balland, Pierre-Alexandre
  • 2014 Konjunkturtest im Fokus: Herstellung von Gummi- und Kunststoffwaren
    by Evgenia Kudymowa & Klaus Wohlrabe
  • 2014 Consumer Inertia and Firm Pricing in the Medicare Part D Prescription Drug Insurance Exchange
    by Keith M. Marzilli Ericson
  • 2013 Inter-firm R&D networks in pharmaceutical biotechnology: What determines firm's centrality-based partnering capability
    by Krogmann, Yin & Riedel, Nadine & Schwalbe, Ulrich
  • 2013 La chimie verte: une nouvelle industrie de substitution GREEN CHEMISTRY: A NEW INDUSTRY OF SUBSTITUTE
    by Clément WILS
  • 2013 Business and Intellectual Capital Development in Financial Riptide - Case Studies of Finnish Biotechnology and Pharmaceutical Companies Dispersing into Global Value Chains
    by Kulvik, Martti & Tähtinen, Marja & Ylä-Anttila, Pekka
  • 2013 The Effects of Drug Enforcement on Violence in Colombia 1999-2010: A Spatial Econometric Approach
    by Botero Degiovanni, Hernan
  • 2013 Environmental Bio Economic Impact in Nicaragua
    by Blanco Orozco, Napoleón Vicente & Zuniga Gonzalez, Carlos Alberto
  • 2013 Proximity, network formation and inventive performance: in search of the proximity paradox
    by Cassi, Lorenzo & Plunket, Anne
  • 2013 Explorative Versus Exploitative Alliances—Evidence From The Glass Industry In China
    by Leung, Vincent K.K. & Lau, Chi Keung Marco & Zhang, Zhe
  • 2013 Pharmaceutical Followers
    by Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley
  • 2013 The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity
    by Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro
  • 2013 Price Indexes for Clinical Trial Research: A Feasibility Study
    by Ernst R. Berndt & Iain M. Cockburn
  • 2013 Behind the Scenes: Sources of Complementarity in R&D
    by Marco Ceccagnoli & Matthew J. Higgins & Vincenzo Palermo
  • 2013 Drug launch timing and international reference pricing
    by Nicolas Houy & Izabela Jelovac
  • 2013 Drug launch timing and international reference pricing
    by Nicolas Houy & Izabela Jelovac
  • 2013 Relatedness and Technological Change in Cities: The rise and fall of technological knowledge in U.S. metropolitan areas from 1981 to 2010
    by Ron Boschma & Pierre-Alexandre Balland & Dieter Franz Kogler
  • 2013 Scientific Knowledge Dynamics and Relatedness in Bio-Tech Cities
    by Ron Boschma & Gaston Heimeriks & Pierre-Alexandre Balland
  • 2013 The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence
    by Frank Lichtenberg & Gisela Hostenkamp
  • 2013 Pharmaceutical regulation and innovative performance: a decision-theoretic model
    by Tannista Banerjee & Stephen Martin
  • 2013 The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry
    by Tannista Banerjee & Ralph Siebert
  • 2013 Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data
    by Niels Skipper & Rune Vejlin
  • 2013 The Relative Role of Imports and Exports in Explaining Productivity of Indian Bio-Pharmaceutical Firms: Evidence from Non Parametric Data Envelopment Analysis
    by Arpita Ghose & Chandrima Chakraborti
  • 2013 Technical efficiency of Russian plastic and rubber production firms
    by Ipatova, Irina & Peresetsky, Аnatoly
  • 2013 Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case
    by CABIEDES MIRAGAYA, LAURA
  • 2013 Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?
    by de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges
  • 2013 Multi-market contact and competition: evidence from the Depression-era portland cement industry
    by Chicu, Mark & Ziebarth, Nicolas L.
  • 2013 Pharmaceutical followers
    by Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B.
  • 2013 Information content of advertising: Empirical evidence from the OTC analgesic industry
    by Anderson, Simon P. & Ciliberto, Federico & Liaukonyte, Jura
  • 2013 Informing the uninformed: How drug advertising affects check-up visits
    by Hosken, Daniel & Wendling, Brett
  • 2013 Direct-to-consumer advertising and consumer welfare
    by Jayawardhana, Jayani
  • 2013 Margins and market shares: Pharmacy incentives for generic substitution
    by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune
  • 2013 Mandatory disclosure of plant emissions into the environment and worker chemical exposure inside plants
    by Finger, Stephen R. & Gamper-Rabindran, Shanti
  • 2013 Identification of External Critical Success Factors in Microbial Biotechnology Firms
    by Alireza AZIMI
  • 2013 Can Financial Engineering Cure Cancer?
    by David E. Fagnan & Jose Maria Fernandez & Andrew W. Lo & Roger M. Stein
  • 2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
    by Renault, Régis & Liaukonyte, Jura & Ciliberto, Federico & Anderson, Simon
  • 2012 Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures
    by Degrassat-Théas, Albane & Bensadon, M. & Rieu, C. & Angalakuditi, M. & Le Pen, Claude & Paubel, Pascal
  • 2012 Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
    by MAZUMDAR, MAINAK & RAJEEV, MEENAKSHI & RAY, SUBHASH C.
  • 2012 Launching prices for new pharmaceuticals in heavily regulated and subsidized markets
    by Jaume Puig & Beatriz González López-Valcárcel
  • 2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
    by Berndt, Ernst & Dubois, Pierre
  • 2012 The Role of the South African Government in Developing the Biotechnology Industry – from Biotechnology Regional Innovation Centres to the Technology Innovation Agency
    by Ramazan Uctu & Hassan Essop
  • 2012 Engineering Knowledge
    by Nathan Rosenberg & W. Edward Steinmuller
  • 2012 How Do The Institutions Involved In Scientific Collaboration Deal With Different Kinds Of Distance? An Analysis Of The Co-Autorships Of Scientific Publications
    by Rosamaria D’Amore & Roberto Iorio & Sandrine Labory & Agnieszka Stawinoga
  • 2012 Who And Where Are The Co-Authors? The Relationship Between Institutional And Geographical Distance In Scientific Publications
    by Rosamaria D’Amore & Roberto Iorio & Agnieszka Stawinoga
  • 2012 Le rôle de l’Etat dans la promotion du secteur pharmaceutique en Algérie: que nous enseigne l’approche par les systèmes sectoriels d’innovation THE ROLE OF THE STATE IN THE PROMOTION OF THE PHARMACEUTICAL SECTOR IN ALGERIA: WHAT DOES THE SECTORAL SYSTEMS OF INNOVATION APPROACH TEACH US?
    by Samia GHARBI
  • 2012 Competitiveness and future challenges of Pohjois-Savo - A report for The Regional Council of Pohjois-Savo (in Finnish with English abstract and summary)
    by Hernesniemi, Hannu & Kulvik, Martti & Ylä-Anttila, Pekka
  • 2012 A Comparative Analysis of Biotechnology Startups between Japan and the US
    by Motohashi, Kazuyuki
  • 2012 Research collaboration in co-­inventor networks: combining closure,bridging and proximities
    by Cassi, Lorenzo & Plunket, Anne
  • 2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
    by Anderson, Simon & Ciliberto, Federico & Liaukonyte, Jura & Renault, Regis
  • 2012 The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey
    by Frank R. Lichtenberg
  • 2012 R&D for Neglected Diseases
    by Nicola Dimitri
  • 2012 Entry Time Effects and Follow-on Drugs Competition
    by Luiz Flavio Andrade
  • 2012 Déterminants de l’écart de prix entre médicaments similaires et le premier entrant d’une classe thérapeutique
    by Christine Sorasith & Sylvain Pichetti & Thomas Cartier & Laure Bergua & Catherine Sermet
  • 2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
    by Berndt, Ernst & Dubois, Pierre
  • 2012 The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals
    by Granlund, David
  • 2012 The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals
    by Granlund, David
  • 2012 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?
    by Granlund, David & Yesim Köksal, Miyase
  • 2012 Regional trajectories of innovation in Green Chemistry: Evidence from the Aquitaine region (In French)
    by Vanessa OLTRA & Maïder SAINT-JEAN
  • 2012 Mapping the scientific knowledge of the Green Chemistry community (In French)
    by Marianna EPICOCO (GREThA, CNRS, UMR 5113) & Vanessa OLTRA (GREThA, CNRS, UMR 5113) & Maïder SAINT JEAN (GREThA, CNRS, UMR 5113)
  • 2012 Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland
    by Aki Kangasharju & Joni Hokkanen & Ismo Linnosmaa & Hannu Valtonen
  • 2012 The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008
    by Gaston Heimeriks & Ron Boschma
  • 2012 Path-breaking innovations for lung cancer: a revolution in clinical practice
    by Mario Coccia
  • 2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
    by Berndt, Ernst R & Dubois, Pierre
  • 2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
    by Anderson, Simon P & Ciliberto, Federico & Liaukonyte, Jura & Renault, Régis
  • 2012 Hacia una política integral de medicamentos biotecnológicos en Colombia
    by Juan Gonzalo Zapata & Sergio Bernal & Jairo Castillo & Katherine Garzón
  • 2012 The rising Chinese pharmaceutical industry: local champions vs global players
    by Francesca Spigarelli & Hao Way
  • 2012 Margins and Market Shares: Pharmacy Incentives for Generic Substitution
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
  • 2012 The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data
    by Frank Lichtenberg & Billie Pettersson
  • 2012 Launching Prices for New Pharmaceuticals in Heavily Regulated and Subsidized Markets
    by Jaume Puig-Junoy & Beatriz Gonzalez L�pez-Valc�rcel
  • 2012 Investments in Pharmaceuticals Before and After TRIPS
    by Margaret K. Kyle & Anita M. McGahan
  • 2012 Dynamics of Public Policy-Making in Malaysia: The Formulation of National Biotechnology Policy
    by Ravi MAHALINGAM
  • 2012 Quasi-fixed inputs in the Italian manufacturing: The case of the pharmaceutical industry
    by Carbonari, Lorenzo
  • 2012 Research Collaboration and Publication's Citation Impact: Evidence in the Italian Biotech Sector
    by Roberto IORIO & Sandrine LABORY & Daniele PACI
  • 2012 The Impact Of Total Quality Management On Competitive Advantage Of Pharmaceutical Manufacturing Companies In Jordan
    by KAMAL A. M. AL-QUDAH
  • 2012 Energy saving opportunities in Jordanian pharmaceutical industries
    by Mohammad Al-Tahat & Areen Al-Ali
  • 2012 Entry and submarket concentration: empirical evidence from the pharmaceutical industry
    by Maria Letizia Giorgetti
  • 2012 Human resource management for learning through knowledge exploitation and knowledge exploration: Pharmaceuticals in Mexico
    by Santiago, Fernando & Alcorta, Ludovico
  • 2012 The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
    by Toole, Andrew A.
  • 2012 What do drug monopolies cost consumers in developing countries?
    by Hellerstein, Rebecca
  • 2012 Productivity Growth in Some Energy Intensive Manufacturing Industries in India: An Analytical Assessment
    by Sarbapriya Ray
  • 2012 Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-cholesterol Drugs
    by Abe Dunn
  • 2012 The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors
    by Craig L. Garthwaite
  • 2011 Subjective well-being among preadolescents - Evidence from urban China
    by Carlsson, Fredrik & Lampi, Elina & Li, Wanxin & Martinsson, Peter
  • 2011 The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
    by Toole, Andrew A.
  • 2011 Inter-firm R&D networks in the global pharmaceutical biotechnology industry during 1985 - 1998: A conceptual and empirical analysis
    by Krogmann, Yin & Schwalbe, Ulrich
  • 2011 Generic drugs in Spain: price competition vs. moral hazard
    by Ivan Moreno-Torres
  • 2011 What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion
    by Ivan Moreno-Torres
  • 2011 Global Framework for Differential Pricing of Pharmaceuticals
    by Daems, Rutger & Maes, Edith & Ramani, Shyama V.
  • 2011 Mapping the interdisciplinary nature and co-evolutionary patterns in five nano-industrial sectors
    by Wang, Lili & Notten, Ad
  • 2011 Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
    by Mainak Mazumdar & Meenakshi Rajeev & Subhash Ray
  • 2011 Market Size and Pharmaceutical Innovation
    by Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul
  • 2011 Innovation and Corporate Dynamics: A Theoretical Framework
    by Jakub Growiec & Fabio Pammolli & Massimo Riccaboni
  • 2011 A Few Special Cases: Scientific Creativity and Network Dynamics in the Field of Rare Diseases
    by Massimo Riccaboni & Maria Laura Frigotto
  • 2011 Inefficiencies in technology transfer: theory and empirics
    by Marie-Laure Allain & Margaret K. Kyle & Emeric Henry
  • 2011 Determinants of drug launch delay in pre-TRIPS India: A survival analysis approach
    by Saradindu Bhaduri & Thomas Brenner
  • 2011 Accumulation and Circulation of the Knowledge Needed for Biotech Business Promotion by Engineers of R&D Section in an IT Enterprise: The Case of Hitachi Software Engineering Co., Ltd
    by Ohta, Hirofumi & Motohashi, Kazuyuki
  • 2011 Gravity and extended gravity: estimating a structural model of export entry
    by Morales, Eduardo & Sheu, Gloria & Zahler, Andrés
  • 2011 Innovation and Corporate Dynamics: A Theoretical Framework
    by Massimo, Riccaboni & Jakub, Growiec & Fabio, Pammolli
  • 2011 Trade and Innovation: Pharmaceuticals
    by Nobuo Kiriyama
  • 2011 Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
    by Patricia M. Danzon & Michael F. Furukawa
  • 2011 A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets
    by Ernst R. Berndt & Thomas G. McGuire & Joseph P. Newhouse
  • 2011 Explaining vertical integration in the generic pharmaceutical industry
    by Kensuke Kubo
  • 2011 Market Size and Pharmaceutical Innovation
    by Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul
  • 2011 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?
    by Granlund, David & Yesim Köksal, Miyase
  • 2011 Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?
    by Granlund, David & Köksal , Miyase Yesim
  • 2011 Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?
    by Granlund, David & Köksal, Miyase Yesim
  • 2011 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals. What's blame? Derogation or perception?
    by Granlund, David & Yesim Köksal, Miyase
  • 2011 Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals
    by Granlund, David & Yesim Köksal, Miyase
  • 2011 The Dynamics of the Inventor Network in German Biotechnology: Geographical Proximity versus Triadic Closure
    by Anne L.J. Ter Wal
  • 2011 External referencing and pharmaceutical price negociation
    by Garcia Marinoso, Begona & Jelovac, Izabella & Olivella, Pau
  • 2011 On the institutional innovation process : EU regulation through an evolutionary lens
    by Evita Paraskevopoulou
  • 2011 Investments in Pharmaceuticals Before and After TRIPS
    by Kyle, Margaret K & McGahan, Anita M
  • 2011 Market Size and Pharmaceutical Innovation
    by de Mouzon, Oliver & Dubois, Pierre & Scott Morton, Fiona & Seabright, Paul
  • 2011 Inefficiencies in technology transfer: theory and empirics
    by Allain, Marie-Laure & Henry, Emeric & Kyle, Margaret K
  • 2011 Seguimiento Al Desarrollo Tecnológico A Través De Patentes: El Caso De La Biotecnología
    by Claudia Nelcy Jiménez Hernández
  • 2011 Multiscalar Clusters And Networks As The Foundations Of Innovation Dynamics In The Biopharmaceutical Industry
    by Marc-Hubert DEPRET & Abdelillah HAMDOUCH
  • 2011 An Application of Economic Capacity Utilization to the Measurement of Total Factor Productivity Growth: Empirical Evidence from Indian Fertilizer Industry
    by Sarbapriya, Ray & Mihir, Kumar Pal
  • 2011 Growth and Financing Behaviour of Firms of Textile Industry in Pakistan: A Panel Data Analysis
    by Ijaz Hussain
  • 2011 The Production Of Medicines In Romania After 1990. What'S The Reason For Imports?
    by Unita Lucian & Straciuc Oreste & Maghiar Teodor Traian & Uivarosan Diana
  • 2011 Strategic Development Trends in the World Pharmaceutical Industry
    by Dragan Kesic
  • 2011 Spatial collocation and venture capital in the US biotechnology industry
    by Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas
  • 2011 Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
    by Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune
  • 2011 Too Many Products: Decentralized Decision Making in Multinational Firms
    by Catherine Thomas
  • 2011 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
    by Glenn Ellison & Sara Fisher Ellison
  • 2010 Inter-organizational collective learning: the case of biotechnology in France
    by Pina-Stranger, Alvaro & Lazega, Emmanuel
  • 2010 The impact of pricing and patent expiration on the demand for pharmaceuticals: An examination of the use of broad-spectrum antimicrobials
    by Kaier, Klaus
  • 2010 Opportunities and Benefits as Determinants of the Direction of Scientific Research
    by Mikko Packalen & Jay Bhattacharya
  • 2010 Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico
    by Santiago-Rodriguez, Fernando & Dutrenit, Gabriela
  • 2010 Child Externalising and Internalising Behaviour in the First Year of School: The Role of Parenting in a Low SES Population
    by Carly Cheevers & Orla Doyle & Kelly McNamara
  • 2010 Decomposing Gender Differences in College Student Earnings Expectations
    by Liam Delaney & Colm Harmon & Cathy Remond
  • 2010 Size Metrics and Dynamics of Firms Expansion in the European Pharmaceutical Industry
    by Franco Mariuzzo & Xiaoheng Zhang
  • 2010 External Price Benchmarking vs. Price Negotiation for Pharmaceuticals
    by Philipp Ackermann
  • 2010 The Study Of Biochemical Parameters For Naval Academy Team In The Naval Pentathlon
    by Virgil ENE-VOICULESCU & Carmen ENE-VOICULESCU
  • 2010 Diversity in firms’ innovation strategies and activities: Main findings of interviews and implications in the context of the Hungarian national
    by Havas, Attila
  • 2010 Trade and Innovation: Report on the Chemicals Sector
    by Nobuo Kiriyama
  • 2010 Margins and Market Shares:Pharmacy Incentives for Generic Substitution
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
  • 2010 Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
    by Ernst R. Berndt & Murray L. Aitken
  • 2010 Pricing and Reimbursement in U.S. Pharmaceutical Markets
    by Ernst R. Berndt & Joseph P. Newhouse
  • 2010 Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
    by Mark Trusheim & Murray L. Aitken & Ernst R. Berndt
  • 2010 Has medical innovation reduced cancer mortality?
    by Frank R. Lichtenberg
  • 2010 Success in Pharmaceutical Research: The Changing Role of Scale and Scope Economies, Spillovers and Competition
    by Tatiana Plotnikova
  • 2010 Productivity and Heterogeneous Knowledge: Exploring the Relationship in a Sample of Drug Developers
    by Giulio Bottazzi & Tatiana Plotnikova
  • 2010 Inferring the Effects of Vertical Integration from Entry Games : An Analysis of the Generic Pharmaceutical Industry
    by Kubo, Kensuke
  • 2010 The More You Spend, the More You Get? The Effects of R&D and Capital Expenditures on the Patenting Activities of Biotechnology Firms
    by Roberta Piergiovanni & Enrico Santarelli
  • 2010 R&D Portfolios and Pharmaceutical Licensing
    by Junichi Nishimura & Yosuke Okada
  • 2010 Margins and Market Shares: Pharmacy Incentives for Generic Substitution
    by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune
  • 2010 The Battle for Patent Rights in Plant Biotechnology: Evidence from Opposition
    by Schneider, Cédric
  • 2010 Pricing and Reimbursement in U.S. Pharmaceutical Markets
    by Berndt, Ernst R. & Newhouse, Joseph P.
  • 2010 Political contributions to influence consumers: the example of the u.s. drug reimportation debate
    by Anne Boring
  • 2010 Effet de l’introduction du système de prix de référence en Tunisie sur les prix des médicaments
    by Ayadi, Inès
  • 2010 The impact of reference pricing system on brand name’s prices : the case of Tunisia
    by Ayadi, Inès
  • 2010 Determinants of the United States’ trade of pharmaceuticals
    by Boring, Anne
  • 2010 Political Contributions to Influence Consumers: the Example of the U.S. Drug Reimportation Debate
    by Boring, Anne
  • 2010 La structure sociale de l’industrie des biotechnologies en France: une étude des relations inter-organisationnelles au niveau inter-individuel
    by Pina-Stranger, Alvaro
  • 2010 How does the stock market respond to chemical disasters?
    by Capelle-Blancard, Gunther & Laguna, Marie-Aude
  • 2010 A History-Friendly Model of the Evolution of the Pharmaceutical Industry: Technological Regimes and Demand Structure
    by Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni
  • 2010 Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?
    by de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges
  • 2010 Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
  • 2010 Longitudinal Analysis of Generic Substitution
    by Dag Morten Dalen & Marilena Locatelli & Steinar Strøm
  • 2010 The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France
    by Frank Lichtenberg
  • 2010 Alfred Marshall Lecture Intellectual Property Rights Protection in Developing Countries: The Case of Pharmaceuticals
    by Pinelopi Koujianou Goldberg
  • 2010 Risk and Risk Management in Chemical Industry
    by Sanda VISAN
  • 2010 The current biotechnology outlook in Malaysia
    by Khairiah Salwa MOKHTAR & Ravi MAHALINGAM
  • 2010 On the impact of trust on consumer willingness to purchase GM food:Evidence from a European survey
    by Damien Rousselière & Samira Rousselière
  • 2010 Application Of Solid-State Fermentation For Cellulase Enzyme Production Using Trichoderma Viride
    by KIRO MOJSOV
  • 2010 Reliability Assessment And Measures For Resource-Saving In Water Lifting Engine Systems In Uzbekistan
    by OLEG GLOVATSKY & RUSTAM ERGASHEV & BAKHTIER URALOV & HOLMATZHAN ISAKOV
  • 2010 The Effects Of Inorganic Salts On Biosynthesis Of Pectinolytic Enzymes By Aspergillus Niger
    by KIRO MOJSOV &
  • 2010 305 Economists Called to Answer Questionnaire on the Pre-Market Approval of Drugs and Devices
    by Daniel B. Klein & Jason Briggeman
  • 2010 The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
    by Guy David & Sara Markowitz & Seth Richards-Shubik
  • 2010 Modern Medicine and the Twentieth Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs
    by Seema Jayachandran & Adriana Lleras-Muney & Kimberly V. Smith
  • 2010 Network Effects in Biology R&D
    by Joachim Henkel & Stephen M. Maurer
  • 2010 Computer Mediated Transactions
    by Hal R. Varian
  • 2010 The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
    by Mark Duggan & Fiona Scott Morton
  • 2010 Price Indexes, Inequality, and the Measurement of World Poverty
    by Angus Deaton
  • 2010 Contractibility and the Design of Research Agreements
    by Josh Lerner & Ulrike Malmendier
  • 2010(XX) Current Perspectives and Challenges of Biofuel Production and Consumption
    by VICTOR PLATON & SIMONA FRONE & ANDREEA CONSTANTINESCU & SORINA JURIST
  • 2009 Does Increased Price Competition Affect Entry of New Pharmaceutical Products?
    by Granlund, David & Rudholm, Niklas
  • 2009 Price and welfare effects of a pharmaceutical substitution reform
    by Granlund, David
  • 2009 Submarket Dynamics and Innovation: The Case of the U.S. Tire Industry
    by Guido Buenstorf & Steven Klepper
  • 2009 Verteporfin in neovascular amd : real life confirms Clinical trials results
    by Le Pen, Claude & Sambuc, R. & Soubrane, G. & Quentel, G. & Zerouta, S. & Ponthieux, A.
  • 2009 Does pharmaceutical consumption improve health care Status ?
    by Amalric, F. & Hauser, S. & Grandfils, N. & Le Pen, Claude
  • 2009 ¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?
    by Costa-Font, Joan & Kanavos, Panos
  • 2009 Patenting activity in biotechnology and pharmaceuticals: a comparative analysis of the Nordic Countries
    by Enrico Sorisio
  • 2009 How variable is labor input in the Italian manufacturing: the case of the pharmaceutical industry
    by Lorenzo Carbonari
  • 2009 Of Patents and Property
    by James Bessen & Michael J. Meurer
  • 2009 Acceptance of biotechnology and social-cultural implications in Ghana
    by Quaye, Wilhemina & Yawson, Ivy & Yawson, Robert M. & Williams, Irene E.
  • 2009 The U.S. Seed Industustustry: An Exploration of Statistics Highlighting the Economic Cctivity of the U.S. Row Crop Seed Industry
    by Maud Roucan-Kane & Allan Gray
  • 2009 Investments in Pharmaceuticals Before and After TRIPS
    by Margaret Kyle & Anita McGahan
  • 2009 Technology, Competition and the Time of Entry: Diversification Patterns in the Development of New Drugs
    by Tatiana Plotnikova
  • 2009 Technological Diversity and Future Product Diversity in the Drug Industry
    by Uwe Cantner & Tatiana Plotnikova
  • 2009 Evolution 1998-2002 of the antidepressant consumption in France, Germany and the United Kingdom
    by Nathalie Grandfils & Catherine Sermet
  • 2009 What’s on the Table? The Doha Round as of August 2009
    by Matthew Adler & Claire Brunel & Gary Clyde Hufbauer & Jeffrey J. Schott
  • 2009 Surgimiento de actividades de exportación exitosas en México: tres casos específicos
    by Edgar Aragon & Anne Fouquet & Marcia Campos
  • 2009 Surgimiento de actividades de exportación exitosas en Uruguay: cuatro casos específicos
    by Michele Snoeck & Lucia Pittaluga & Hector Pastori & Rosario Domingo & Carlos Casacuberta
  • 2009 The Emergence of Successful Export Activities in Uruguay: Four Case Studies
    by Michele Snoeck & Lucia Pittaluga & Hector Pastori & Rosario Domingo & Carlos Casacuberta
  • 2009 Surgimiento de nuevas actividades de exportación en América Latina: el caso de Chile
    by Manuel Agosin & Claudio Bravo-Ortega
  • 2009 The Emergence of New Successful Export Activities in Latin America: The Case of Chile
    by Manuel Agosin & Claudio Bravo-Ortega
  • 2009 The Emergence of Successful Export Activities in Mexico: Three Case Studies
    by Edgar Aragon & Anne Fouquet & Marcia Campos
  • 2009 Price and welfare effects of a pharmaceutical substitution reform
    by Granlund, David
  • 2009 Finance and Industrial Dynamics (In French)
    by Claude DUPUY (GREThA UMR CNRS 5113) & Matthieu MONTALBAN (GREThA UMR CNRS 5113) & Sylvain MOURA (GREThA UMR CNRS 5113)
  • 2009 How financialisation shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster conception of control (In French)
    by Matthieu MONTALBAN ( (GREThA UMR CNRS 5113)
  • 2009 How financialisation shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster conception of control (In French)
    by Matthieu MONTALBAN (GREThA-GRES)
  • 2009 Entry in the ADHD drugs market: Welfare impact of generics and me-toos
    by Farasat A.S. Bokhari & Gary M. Fournier
  • 2009 An Analysis of the Pricing of Traits in the U.S. Corn Seed Market
    by Shi, Guanming & Chavas, Jean-Paul & Steigert, Kyle
  • 2009 An Analysis of Bundle Pricing in Horizontal and Vertical Markets: The Case of the U.S. Cottonseed Market
    by Shi, Guanming & Stiegert, Kyle & Chavas, Jean-Paul
  • 2009 On Pricing and Vertical Organization of Differentiated Products
    by Shi, Guanming & Chavas, Jean-Paul
  • 2009 L’évaluation multicritère comme aide à l’orientation de la recherche : application aux technologies de stockage embarqué de l'hydrogène
    by Montignac, Florent & Mousseau, Vincent & Bouyssou, Denis & Damart, Sébastien & Aloulou, Mohamed Ali & Rousval, Benjamin
  • 2009 Transfert technologique et processus collectif d'apprentissage dans l'industrie des biotechnologies en France
    by Pina-Stranger, Alvaro
  • 2009 La `dominancia´ alimentaria de la política monetaria, biotecnología y política de tierras
    by Carlos Gustavo Cano
  • 2009 Impact de la réforme de l’assurance maladie en Tunisie sur l’offre et la demande des médicaments
    by Ayadi, Inès
  • 2009 Biofuels: Players and discussions in Latin America
    by Mariana Saidón
  • 2009 Innovation Co-Operation Modes In Hungarian Chemical Industry
    by BEATRIX LANYI
  • 2009 Small is beautiful: deutsche Chemieunternehmen schrumpfen sich produktiv
    by Oleg Badunenko
  • 2009 Ventajas competitivas basadas en la gestión del conocimiento: El caso de tres sectores industriales del departamento del Atlántico
    by José Luis Ramos R. & Rubén Darío Rangel R.
  • 2009 R&D offshoring and clustering dynamics in pharmaceuticals and biotechnology: key features and insights from the Chinese case
    by Abdelillah Hamdouch & Feng He
  • 2009 The Effect of GDP Growth on Pharmaceutical Patent Protection, 1945-2005
    by Summer La Croix & Ming Liu
  • 2008 Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra)
    by Le Pen, Claude & Miadi-Fargier, H. & Fautrel, B. & Maravic, M. & Daures, JP. & Ollivier, AL. & Maurel, F.
  • 2008 Internationalization of biotechnology start-ups: the role of geographical location
    by Lejeune, Albert & Vidot-Delerue, Hélène
  • 2008 Innovation protection mechanisms: the influence of national culture
    by Bérard, Céline & Vidot-Delerue, Hélène
  • 2008 Internationalising to create Firm Specific Advantages: Leapfrogging strategies of U.S. Pharmaceutical firms in the 1930s and 1940s & Indian Pharmaceutical firms in the 1990s and 2000s
    by Athreye, Suma & Godley, Andrew
  • 2008 Experimentation with Strategy and the Evolution of Dynamic Capability in the Indian Pharmaceutical Sector
    by Athreye, Suma & Kale, Dinar & Ramani, Shyama V.
  • 2008 New Europe's Promise for Life Sciences
    by Filippov, Sergey & Kalotay, Kalman
  • 2008 Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico
    by Santiago-Rodriguez, Fernando
  • 2008 The Tunisian Pharmaceutical Sector in Transformation: Inventory of Fixtures and Innovation Prospects
    by Nejla Yacoub
  • 2008 Stratégies d’innovation des firmes des sciences de la vie et appropriation des ressources végétales : processus et enjeux Innovations strategies of firms in life science and appropriation of vegetal resources : process and stakes
    by Blandine Laperche
  • 2008 La lutte anti-blanchiment dans le secteur de l’assurance (the fight against money laundering in the insurance sector)
    by Éric Vernier & Hubert Delval
  • 2008 Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration
    by Ching, Andrew
  • 2008 Policy options of agricultural biotechnology R&D in Sub-Saharan Africa: key issues and aspects
    by Yawson, Robert M. & Yawson, Ivy
  • 2008 Firm dynamic governance of global innovation by means of flexible networks of connections
    by Gay, Brigitte
  • 2008 Overcoming Innovation Limits through Outward FDI: The Overseas Acquisition Strategy of Indian Pharmaceutical Firms
    by Pradhan, Jaya Prakash
  • 2008 Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment
    by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
  • 2008 Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy
    by Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari
  • 2008 Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
    by Patricia M. Danzon & Andrew J. Epstein
  • 2008 Drug price setting and regulation in France
    by Nathalie Grandfils
  • 2008 Home to Market: Response,Resurgence and Transformation of Ayurveda from 1830's to 1920
    by M.S. Harilal
  • 2008 Genetic Codes of Mergers, Post Merger Technology Evolution and Why Mergers Fail
    by Alexander Cuntz
  • 2008 Generic Substitution
    by Furu, Kari & Dalen, Dag Morten & Locatelli, Marilena & Strøm, Steinar
  • 2008 Multinationals in the Knowledge Economy - a case study of AstraZeneca in Sweden
    by Andersson, Martin & Johansson, Börje & Karlsson, Charlie & Lööf, Hans
  • 2008 The European Socio-Economic Models of a Knowledge-based society. \r\nMain findings and conclusion \r\n
    by Bruno AMABLE (Université Paris I and CEPREMAP) & Yannick LUNG (GREThA UMR CNRS 5113 and GERPISA)
  • 2008 The European Socio-Economic Models of a Knowledge-based society. Main findings and conclusions
    by Bruno AMABLE (Université Paris I and CEPREMAP) & Yannick LUNG (GREThA-GRES)
  • 2008 Intellectual property rights in agricultural and agro-food biotechnologies to 2030 (© OECD International Futures Programme)
    by Trommetter, M.
  • 2008 Innovation in India and China : Challenges and Prospects in Pharmaceuticals and Biotechnology
    by Jayan Jose Thomas
  • 2008 On the Effects of Suggested Prices in Gasoline Markets
    by Riemer P. Faber & Maarten C.W. Janssen
  • 2008 Pharmaceutical Research Strategies
    by Sandra Phlippen & An Vermeersch
  • 2008 Investigating Generic and Brand Name Pharmaceutical’s Market Shares and Prices in Tunisia
    by Chebbi, Houssem Eddine & Boujelbene, Younes & Ayadi, Inès
  • 2008 Stratégies de R et D et innovation dans l’industrie pharmaceutique en France : une étude économétrique sur données individuelles
    by Zouikri, Messaoud
  • 2008 A hybrid methodology for the Cox proportional hazard model
    by Marianela Luzardo Briceño
  • 2008 Geographic and Temporal Heterogeneity in Public Prescription Pharmaceutical Expenditures in Spain
    by Lauridsen, Jorgen & Bech, Mickael & Lopez, Fernando & Mate Sanchez, Mariluz
  • 2008 Selbstselektion statt Personalauswahl? Auslandsentsendungen in der deutschen chemischen Industrie
    by Heiner Minssen & Susanne Schmidt
  • 2008 The Determinants of Capital Structure of the Chemical Industry in Pakistan
    by Muhammad Rafiq & Asif Iqbal & Muhammad Atiq
  • 2008 Critical Success Factors for Intra-Disciplinary Transformation of the Agricultural Biotechnology Industry in Taiwan based on the Value Chain Concept
    by Meng-Shiunn Lee
  • 2008 Course technologique et valeur boursière. Une étude d'événements basée sur l'industrie pharmaceutique
    by Sandy Campart & Étienne Pfister
  • 2007 Pratique de la méthodologie MACBETH en situation d’experts multiples : le cas de l’évaluation des technologies de stockage d’hydrogène
    by Montignac, Florent & Aloulou, Mohamed Ali & Damart, Sébastien & Rousval, Benjamin & Mousseau, Vincent & Bouyssou, Denis
  • 2007 Positionierung der deutschen Industrie im globalen Konsolidierungsprozess : im Auftrag des Bundesministeriums für Wirtschaft und Technologie
    by Michael Reinhard & Hans Schedl & Achim Buchwald & Ralph Henger
  • 2007 Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR program
    by Czarnitzki, Dirk & Toole, Andrew A.
  • 2007 Restructuring of Energy-intensive Industrial Branches in Romania and Proposals for Industrial Policy Measures
    by Edward Christie & Gabor Hunya & Waltraut Urban
  • 2007 Generic entry into a regulated pharmaceutical market
    by Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué
  • 2007 Multimarket contact in pharmaceutical markets
    by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín
  • 2007 The determinants of pricing in pharmaceuticals: Are U.S. prices really higher than those of Canada?
    by Antonio Cabrales & Sergi Jiménez-Martín
  • 2007 Generic entry into a regulated pharmaceutical market
    by Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué
  • 2007 Brevet, innovation modulaire et collaboration : Le cas des vaccins géniques
    by Antoine Bureth & Moritz Mueller & Julien Pénin & Sandrine Wolff
  • 2007 The Emergence of new Successful Export Activities in Uruguay
    by Michele Snoeck & Carlos Casacuberta & Rosario Domingo & Héctor Pastori & Lucía Pittaluga
  • 2007 Simulaatio lääkekehitysalan kannattavuudesta ja riskeistä
    by Hermans, Raine & Kulvik, Martti
  • 2007 Imposing a unilateral carbon constraint on European energy-intensive industries and its impact on their international competitiveness - data & analysis
    by Bergmann, Manfred & Schmitz, Andreas & Hayden, Mark & Kosonen, Katri
  • 2007 Betweenness Centrality of Fractal and Non-Fractal Scale-Free Model Networks and Tests on Real Networks
    by Kitsak, Maksim & Havlin, Shlomo & Paul, Gerald & Riccaboni, Massimo & Pammolli, Fabio & Stanley, H. Eugene
  • 2007 Financial Risk in the Biotechnology Industry
    by Joseph H. Golec & John A. Vernon
  • 2007 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
    by Glenn Ellison & Sara Fisher Ellison
  • 2007 Effects of 'Authorized-Generics' on Canadian Drug Prices
    by Paul Grootendorst
  • 2007 The Relationship among innovative Output, Productivity, and Profitability. A test comparing USPTO and EPO data
    by Enrico Santarelli & Francesca Lotti
  • 2007 Economic Policy in Health Care: Sickness Absence and Pharmaceutical Cost
    by Granlund, David
  • 2007 Consumer Information and Pharmaceutical Prices: Theory and Evidence
    by Granlund, David & Rudholm, Niklas
  • 2007 Consumer Information and Pharmaceutical Prices: Theory and Evidence
    by Granlund, David & Rudholm, Niklas
  • 2007 Incrementalism of environmental innovations versus paradigmatic change: A comparative study of the automotive and chemical industries
    by Vanessa OLTRA (GREThA) & Maïder SAINT JEAN (GREThA)
  • 2007 Incrementalism of environmental innovations versus paradigmatic change: A comparative study of the automotive and chemical industries
    by Vanessa OLTRA (GREThA-GRES) & Maïder SAINT JEAN (GREThA-GRES)
  • 2007 Flexibility in the implementation of intellectual property rights in agricultural biotechnology
    by Trommetter, M.
  • 2007 Indian Innovation Systems and Emergence of Biopharmaceutical Sector : Issues and Prospects
    by Sachin Chaturvedi
  • 2007 Downsizing in German Chemical Manufacturing Industry during the 1990s: Why Small Is Beautiful?
    by Oleg Badunenko
  • 2007 Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
    by Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås
  • 2007 The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really higher than those of Canada?
    by Antonio Cabrales & Sergi Jiménez-Martín
  • 2007 Multimarket Contact in Pharmaceutical Markets
    by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín
  • 2007 Multimarket Contact in Pharmaceutical Markets
    by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín
  • 2007 The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?
    by Antonio Cabrales & Sergi Jiménez-Martín
  • 2007 What is "Business Development"? - The Case of Biotechnology
    by Sonja Kind & Dodo zu Knyphausen-Aufseß
  • 2007 Testing price-fixing agreements in a multimarket context: The European case of vitamin C
    by Balaguer, Jacint & Orts, Vicente & Uriel, Ezequiel
  • 2007 Les déterminants des fusions-acquisitions. Le cas de l'industrie pharmaceutique
    by Gautier Duflos & Étienne Pfister
  • 2006 "Responsible Care" and Sustainable Management: The Reciprocal Influence of Society - Management Practices
    by Berland, Nicolas & Loison, Marie-Claire
  • 2006 Allocative efficiency measurement revisited: do we really need input prices?
    by Badunenko, Oleg & Fritsch, Michael & Stephan, Andreas
  • 2006 Überwindung betriebswirtschaftlicher Defizite im Innoregio-Netzwerk Kunststoffzentrum Westmecklenburg
    by Neunteufel, Herbert & Rössel, Gottfried & Sassenberg, Uwe & Laske, Michael & Kipura, Janine & Brüning, Andreas
  • 2006 Allocative efficiency measurement revisited: Do we really need input prices?
    by Badunenko, Oleg & Fritsch, Michael & Stephan, Andreas
  • 2006 Indian Pharma Within Global Reach?
    by Gehl Sampath, Padmashree
  • 2006 Rough Road to Market: Institutional Barriers to Innovations in Africa
    by Oyelaran-Oyeyinka, Banji & Gehl Sampath, Padmashree
  • 2006 India's product patent protection regime: Less or more of "pills for the poor"?
    by Gehl Sampath, Padmashree
  • 2006 The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    by Mahlich, Jörg C. & Roediger-Schluga, Thomas
  • 2006 Breaking the Fence: Patent Rights and Biomedical Innovation in 'Technology Followers'
    by Gehl Sampath, Padmashree
  • 2006 Knowledge-sourcing strategies for cross-disciplinarity in bionanotechnology
    by Isamel Rafols & Martin Meyer
  • 2006 Riskirahoituksen merkitys biotekniikka-alalla: Pääomasijoittajien vertailu yritysten näkökulmasta
    by Luukkonen, Terttu & Maunula, Mari
  • 2006 Adaption of New Technologies and Costs of Health Care
    by Kulvik, Martti & Linnosmaa, Ismo & Hermans, Raine
  • 2006 Coaching Small Biotech Companies into Success: The Value-adding Function of VC
    by Terttu Luukkonen, & Mari Maunula,
  • 2006 The Perceived Value-added of Venture Capital Investors. Evidence from Finnish Biotechnology Industry
    by Maunula, Mari
  • 2006 Helsingin seudun klusterit sekä erikoistuminen bioteknologiaan ja logistiikkaan
    by Hernesniemi, Hannu & Kulvik, Martti
  • 2006 Private Sector R&D in the New Member States: Hungary
    by Havas, Attila
  • 2006 A Generalized Preferential Attachment Model for Business Firms Growth Rates: I. Empirical Evidence
    by Pammolli, Fabio & Fu, Dongfeng & Buldyrev, Sergey V. & Riccaboni, Massimo & Matia, Kaushik & Yamasaki, Kazuko & Stanley, H. Eugene
  • 2006 A Generalized Preferential Attachment Model for Business Firms Growth Rates: II. Mathematical Treatment
    by Buldyrev, Sergey V. & Pammolli, Fabio & Riccaboni, Massimo & Yamasaki, Kazuko & Fu, Dongfeng & Matia, Kaushik & Stanley, H. Eugene
  • 2006 Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies
    by Pradhan, Jaya Prakash
  • 2006 Overseas Acquisition versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
    by Pradhan, Jaya Prakash & Alakshendra, Abhinav
  • 2006 Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
    by Jeffrey L. Furman & Margaret K. Kyle & Iain M. Cockburn & Rebecca Henderson
  • 2006 Openness and Industrial Responses in a Wal-Mart World: A Case Study of Mexican Soaps, Detergents and Surfactant Producers
    by Beata Smarzynska Javorcik & Wolfgang Keller & James R. Tybout
  • 2006 Did Medicare Induce Pharmaceutical Innovation?
    by Daron Acemoglu & David Cutler & Amy Finkelstein & Joshua Linn
  • 2006 R&D in the Belgian Pharmaceutical Sector
    by Helga De Doncker
  • 2006 Jüngere Entwicklungen auf dem Risikokapitalmarkt für Biotechnologie in Deutschland
    by Simeon Schudy
  • 2006 Indian Patent Policy and Publich Health : implications from the Japanese Experience
    by Aoki, Reiko & Kubo, Kensuke & Yamane, Hiroko
  • 2006 The Pharmacia Story of Entrepreneurship and as a Creative Technical University - An Experiment in Innovation, Organizational Break Up and Industrial Renaissance
    by Eliasson, Gunnar & Eliasson, Åsa
  • 2006 Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
    by Brekke, Kurt R. & Grasdal, Astrid L. & Holmås, Tor Helge
  • 2006 FDI and Spillover Effects in the Indian Pharmaceutical Industry
    by Annika Bergman
  • 2006 Allocative Efficiency Measurement Revisited: Do We Really Need Input Prices?
    by Oleg Badunenko & Michael Fritsch & Andreas Stephan
  • 2006 The Dye Famine and its Aftermath: Knowledge Diffusion and Entry
    by Genesove, David
  • 2006 Estudio sobre la propiedad intelectual en el sector farmacéutico colombiano
    by Emilio Archila & Gabriel Carrasquilla & Marcela Meléndez & Juan Pablo Uribe
  • 2006 Reference Pricing of Pharmaceuticals
    by Kurt R. Brekke & Ingrid Königbauer & Odd Rune Straume
  • 2006 Research Strategies in Science-based Start-ups - Effects on performance in Danish and Swedish biotechnology
    by Finn Valentin & Henrich Dahlgren & Rasmus Lund Jensen
  • 2006 La propriété intellectuelle dans les biotechnologies agricoles : quels enjeux pour quelles perspectives ?
    by Michel Trommetter
  • 2006 Comment favoriser l'innovation dans le secteur pharmaceutique : brevets et/ou récompenses ?
    by Paul Belleflamme & Tanguy van Ypersele
  • 2006 Intégration technologique et valeur boursière des firmes de biotechnologies
    by Lionel Nesta & Pier-Paolo Saviotti
  • 2006 Biotechnologies et industrie pharmaceutique. Un modèle évolutionnaire conforme à l'histoire
    by Franco Malerba & Luigi Orsenigo & Sandrine Selosse
  • 2006 On the Life Cycle of Knowledge Intensive Sectors
    by Thomas Grebel & Jackie Krafft & Pier-Paolo Saviotti
  • 2006 The Evolution of Geographic Structure in New Industries
    by Steven Klepper
  • 2005 L'histoire mouvementée d'un rapprochement : Sanofi - Aventis
    by Perrot, Serge & Blanchot, Fabien
  • 2005 Unilateral commitments in European biotechnology alliances : a real option approach
    by Vidot-Delerue, Hélène
  • 2005 Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D
    by Toole, Andrew A.
  • 2005 Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry
    by Fier, Andreas & Heneric, Oliver
  • 2005 Functional Foods In The European Union: An Overview Of The Sector'S Main Issues
    by Alessandra CASTELLINI & Maurizio Canavari & Carlo Pirazzoli
  • 2005 Production of a New Drug: A Sequential Investment ProcessUnder Uncertainty
    by Marcello Basili & Roberto Renò & Carlo Zappia
  • 2005 Technological Characteristics and R&D Alliance Form: Evidence from the U.S. Biotechnology Industry
    by Xia Wang
  • 2005 Phases of Imitation and Innovation in a North-South Endogenous Growth Model
    by Daniel Rais & Jonathan Goldman
  • 2005 “Branded Generics” As A Strategy To Limit Cannibalization Of Pharmaceutical Markets
    by Michael R. Ward & David Reiffen
  • 2005 Innovation Paths of Estonian Biotechnology
    by Tõnis Mets
  • 2005 Consequences of the IPPC-directive’s BAT requirements for abatement costs and emissions
    by Jan Larsson & Kjetil Telle
  • 2005 The Growth of Business Firms: Theoretical Framework and Empirical Evidence
    by Fu, Dongfeng & Pammolli, Fabio & Buldyrev, Sergey V. & Riccaboni, Massimo & Matia, Kaushik & Yamasaki, Kazuko & Stanley, H. Eugene
  • 2005 Trips and Patenting Activity: Evidence from the Indian Pharmaceutical Industry
    by Alka Chadha
  • 2005 Product cycles, innovation and exports: A study of Indian pharmaceuticals
    by Alka Chadha
  • 2005 Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending
    by Joseph Golec & Shantaram Hegde & John A. Vernon
  • 2005 Socio-economic Impact of Nanoscale Science: Initial Results and NanoBank
    by Lynne G. Zucker & Michael R. Darby
  • 2005 Parallel Imports, Drag Price Control and Pharmaceutical Innovation
    by Ken Tabata & Testuya Shinkai & Satoru Tanaka & Makoto Okamura
  • 2005 Who Develops Innovations in Medicine for the Poor? Trends in Patent Applications Related to Medicines for HIV/AIDS, Tuberculosis, Malaria and Neglected Diseases
    by Ito, Banri & Yamagata, Tatsufumi
  • 2005 Testing Collusive Prices In A Multimarket Context: The European Case Of Vitamin C
    by Jacint Balaguer & Ezequiel Uriel Jiménez & Vicente Orts
  • 2005 Reference Pricing of Pharmaceuticals
    by Brekke, Kurt R & Königbauer, Ingrid & Straume, Odd Rune
  • 2005 Start-ups, firm growth and the consolidation of the French biotech industry
    by Avenel, E. & Corolleur, F. & Gauthier, C. & Rieu, C.
  • 2005 Knowledge and Productivity in the World's Largest Manufacturing Corporations Level:Panel Data analysis on Compustat and Patent data
    by Lionel Nesta
  • 2005 Biosafety Protocol, International Trade and Agricultural Biotechnology : Policy Inferences for India
    by Sachin Chaturvedi & Lian Chawii
  • 2005 State of Competition in the Wholesale and Retail Sector
    by Ma. Teresa Dueñas-Caparas
  • 2005 Empirical Tests of Optimal Cognitive Distance
    by Wuyts, S.H.K. & Colombo, M. & Dutta, S. & Nooteboom, B.
  • 2005 Density and Strength of Ties in Innovation Networks: An Analysis of Multi-Media and Biotechnology
    by Gilsing, V.A. & Nooteboom, B.
  • 2005 « Responsible Care» et management durable: comportement volontaire ou réaction adaptative ? Généalogie et pratiques dans l'industrie chimique
    by Berland, Nicolas & Loison, Marie-Claire
  • 2005 Generic Drug Industry Dynamics
    by David Reiffen & Michael R. Ward
  • 2005 Strategic Reasons for Patenting: Between Exclusion and Coordination Rationales
    by Antoine Bureth & Rachel Levy & Julien Pénin & Sandrine Wolff
  • 2004 Price Regulation and Competition in Japanese Pharmaceutical Market
    by Tomofumi & Anegawa
  • 2004 Processus d'évolution d'un district industriel : le cas de la cosmetic valley (France)
    by Huault, Isabelle & Barabel, Michel & Meier, Olivier
  • 2004 Biotechnology in New Zealand
    by Dan Marsh
  • 2004 Biotechnology in New Zealand
    by Dan Marsh
  • 2004 Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
    by Joan Costa & Jaume Puig
  • 2004 Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
    by Joan Costa & Jaume Puig
  • 2004 Estudios de competitividad sectoriales. Industria manufacturera
    by María Inés Terra & Gustavo Bittencourt & Rosario Domingo & Carmen Estrades & Gabriel Katz & Alvaro Ons & Héctor Pastori
  • 2004 Optimal Intellectual Property Rights Protection and Humanitarian Assistance during and International Health Emergency
    by Drusilla K. Brown & George Norman
  • 2004 Persistent Knowledge Specialisation and Intra-Industry Heterogeneity: an Analysis of the Spanish Pharmaceutical Industry
    by Pablo D'Este Cukierman
  • 2004 FDI spillovers and local productivity growth: evidence from Indian pharmaceutical industry
    by Pradhan, Jaya Prakash
  • 2004 Market Structure and Drug Innovation
    by Pammolli, Fabio & Riccaboni, Massimo
  • 2004 Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure
    by Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo
  • 2004 Preferential attachment and growth dynamics in complex systems
    by Yamasaki, Kazuko & Matia, Kaushik & Buldyrev, Sergey V. & Fu, Dongfeng & Pammolli, Fabio & Riccaboni, Massimo & Stanley, H. Eugene
  • 2004 The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program
    by Frank R. Lichtenberg
  • 2004 Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
    by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck
  • 2004 Vertical Product Differentiation, Market Entry, and Welfare
    by Reisinger, Markus
  • 2004 Competence in Health Care - An Industrial Systems Analysis Using Competence Bloc Theory to Compare European and US Health Care
    by Eliasson, Gunnar & Eliasson, Åsa
  • 2004 The Norwegian market for pharmaceuticals and the non-mandatory substitution reform of 2001: the case of enalapril
    by Razzolini, Tiziano
  • 2004 The Origin and Location of Entrants in the Evolution of the U.S. Tire Industry
    by G. Buenstorf & S. Klepper
  • 2004 A Dynamic Oligopoly Structural Model for the Prescription Drug Market After Patent Expiration
    by Andrew Ching
  • 2004 Las patentes aceleran o retrasan la comercializacion de nuevos medicamentos en los paises en desarrollo?
    by Joan Ramon Borrell Arque
  • 2004 Price Competition in Pharmaceuticals: The Case of Anti-infectives
    by Steven N. Wiggins & Robert Maness
  • 2004 La gouvernance des jeunes entreprises innovantes:un éclairage analytique à partir du cas des sociétés de biotechnologies
    by Marc-Hubert Depret & Abdelillah Hamdouch
  • 2004 L'interaction des dynamiques individuelles et collectives dans le processus de développement territorial
    by Sophie-Hélène Bataïni
  • 2003 Die Bedeutung von Patentschutz für den Technologietransfer in Entwicklungsländer : Erfahrungen der chemischen Industrie in Südkorea, Malaysia und Chile im Vergleich
    by Thomas Röhm
  • 2003 Das Marketingniveau in der Kunststoffbranche Westmecklenburgs
    by Neunteufel, Herbert & Rössel, Gottfried & Sassenberg, Uwe
  • 2003 International Price-Fixing Cartels and Developing Countries: A Discussion of Effects and Policy Remedies
    by Margaret Levenstein & Valerie Suslow & Lynda Oswald
  • 2003 Pharmaceutical generics, vertical product differentiation and public policy
    by Antonio Cabrales
  • 2003 Pharmaceutical generics, vertical product differentiation and public policy
    by Antonio Cabrales
  • 2003 Optimal Intellectual Property Rights Exhaustion and Humanitarian Assistance during a National Health Emergency
    by Drusilla K. Brown & George Norman
  • 2003 The Knowledge Bases of the World's Largest Pharmaceuticals Groups: what do Patent Citations to Non-Patent Literature Reveal?
    by Stefano Brusoni & Paola Criscuolo & Aldo Geuna
  • 2003 Intangible Assests and Market Value: Evidence from Biotechnology Firms
    by Lionel Nesta & Pier-Paolo Saviotti
  • 2003 Reverse Technology Transfer: A Patent Citation Analysis of the European Chemical and Pharmaceutical Sectors
    by Paola Criscuolo
  • 2003 The Effects of Environmental Regulation On Technology Diffusion: The Case of Chlorine Manufacturing
    by Stavins, Robert & Snyder, Lori & Miller, Nolan
  • 2003 Liberalization, Firm Size and R&D performance: A Firm Level Study of Indian Pharmaceutical Industry
    by Pradhan, Jaya Prakash
  • 2003 On Size and Growth of Business Firms
    by De Fabritiis, Gianni & Riccaboni, Massimo & Pammolli, Fabio
  • 2003 TRIPS and the Pharmaceutical Industry in Bangladesh: Towards a National Strategy
    by Professor Tony VanDuzer
  • 2003 Pharmaceutical Use and Expenditure for Cardiovascular Disease and Stroke: A Study of 12 OECD Countries
    by Michael Dickson & Stéphane Jacobzone
  • 2003 Uncertainty in the Generic Versus Brand Name Prescription Decision
    by Hellström, Jörgen & Rudholm, Niklas
  • 2003 Titanium Implants – A Comparison of a Swedish and an Ohio Firm
    by Fridh, Ann-Charlotte
  • 2003 Direct-to-Consumer Advertising in Pharmaceutical Markets
    by Brekke, Kurt R. & Kuhn, Michael
  • 2003 The Effects of Environmental Regulation on Technology Diffusion: The Case of Chlorine Manufacturing
    by Lori Snyder & Nolan Miller & Robert Stavins
  • 2003 Globalisation and Its Impact on Competitiveness: the Case of the British and German Pharmaceutical Industry
    by Christel Lane & Jocelyn Probert
  • 2003 Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy
    by Antonio Cabrales
  • 2003 Reference prices: The Spanish way
    by Jorge Mestre
  • 2002 Erfolgsabhängige Vergütung: Ein sicherer Weg zur Steigerung der Leistung von Top-Managern?
    by Zwick, Thomas & Wolf, Elke & Beblo, Miriam
  • 2002 Does New Zealand have an Innovation System for Biotechnology?
    by Dan Marsh
  • 2002 Does New Zealand have an Innovation System for Biotechnology?
    by Dan Marsh
  • 2002 Economic Insights and Deficits in European Biotechnology Patent Policy
    by Gilroy, Bernard Michael & Volpert, Tobias
  • 2002 Economic Insights and Deficits in European Biotechnology Patent Policy
    by Gilroy, Bernard Michael & Vollpert, Tobias
  • 2002 A Comparison of U.S. and European University-Industry Relations in the Life Sciences
    by Owen-Smith, Jason & Riccaboni, Massimo & Pammolli, Fabio & Powell, Walter W.
  • 2002 Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health"
    by Frank R. Lichtenberg & Suchin Virabhak
  • 2002 Benefits and Costs of Newer Drugs: An Update
    by Frank Lichtenberg
  • 2002 Innovation and Market Structure: An Empirical Evaluation of the 'Bounds Approach' in the Chemical Industry
    by Marín Uribe, Pedro Luis & Siotis, Georges
  • 2002 Biotecnologia: corporações, financiamento da inovação e novas formas organizacionais
    by Silveira, José Maria F. J. da
  • 2002 Mercados de violencia" y guerra civil en América Latina en los 90*"
    by Javier Guerrero Barón
  • 2001 Restricciones Macroeconómicas al Desarrollo Económico y la Reducción de la Pobreza: El Caso de Bolivia
    by Schweickert, Rainer
  • 2001 Innovation et marche financiers: l'impact des avancees therapeutiques sur les rentabilites boursieres des firmes
    by Campart, S. & Pfister, E.
  • 2001 Research Incentives in Competing Markets: A Model of the Development of New Vaccines
    by Rey, P.
  • 2001 The World Trade Organization and Publicly Funded Healthcare in Canada
    by Ostry, A.
  • 2001 Buying Science, Selling Drugs
    by Evans, R.G. & Morgan, S.G. & Barer, M.L.
  • 2001 Do court-ordered breakups spur innovation?
    by Leon Taylor
  • 2001 Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99
    by Dan Marsh
  • 2001 Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99
    by Dan Marsh
  • 2001 On Firm Growth in Networks
    by Riccaboni, Massimo & Pammolli, Fabio
  • 2001 An Empirical Model of Heterogeneous Consumer Search for Retail Prescription Drugs
    by Alan T. Sorensen
  • 2001 The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
    by Frank R. Lichtenberg
  • 2001 Global/local articulation in industrial models for phamaceuticals, automobile and aeronautics (In French)
    by Marie-Claude BÉLIS-BERGOUIGNAN (IFREDE-E3i) & Vincent FRIGANT (IFREDE-E3i) & Damien TALBOT (LEREPS)
  • 2001 The Self-Organisation of Strategic Alliances
    by Andreas Pyka & Paul Windrum
  • 2001 Innovation Networks in the Biotechnology-Based Sectors
    by Andreas Pyka & Paolo Saviotti
  • 2000 How to win Schumpeterian Competition. Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Streb, J.
  • 2000 How to win Schumpeterian Competition. Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Streb, J.
  • 2000 Heternenous Labor Demand and Aggregate Job Flows. Specification, Estimation and Testing with French Data
    by Fairise, X. & Feve, P.
  • 2000 L'utilisation des notions de confiance et de proximite dans l'etude des processus de R&D pharmaceutiques
    by Perrochon, D. & Lebert, D.
  • 2000 Coalitions industrielles, reseaux de firmes et dynamiques de concurrence-cooperation dans les secteurs en cours de globalisation : le cas de l'industrie pharmaceutique
    by Hamdouch, A. & Depret, M.-H.
  • 2000 Fostering Innovation in a Small Open Economy: The Case of the New Zealand Biotechnology Sector
    by Dan Marsh
  • 2000 Fostering Innovation in a Small Open Economy: The Case of the New Zealand Biotechnology Sector
    by Dan Marsh
  • 2000 Heterogeneity in Returns to Scale: A Random Coefficient Analysis with Unbalanced Panel Data
    by Erik Biørn & Kjersti-Gro Lindquist & Terje Skjerpen
  • 2000 The Nature and the Extent of the Market for Technology in Biopharmaceuticals
    by Arora, Ashish & Gambardella, Alfonso & Pammolli, Fabio & Riccaboni, Massimo
  • 2000 Global Competitiveness in Pharmaceuticals: A European Perspective
    by Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio
  • 2000 Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
    by Ernst R. Berndt & Robert S. Pindyck & Pierre Azoulay
  • 2000 Entry and the Number of firms in the Swedish Pharmaceuticals Market
    by Rudholm, Niklas
  • 2000 Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening
    by Franco Malerba & Luigi Orsenigo
  • 2000 Corporate Governance and the Governance of Innovation: the Case of Pharmaceutical Industry
    by Nicola Lacetera
  • 2000 The determinants of pharmaceutical research and development expenditures
    by Henry Grabowski & John Vernon
  • 1999 Aspects économiques du partage des avantages
    by Guillaud, Yann & Swanson, Timothy & Keppler, Jan Horst
  • 1999 An Examination of Technology Strategies for the Integration of Bioinformatics in Pharmaceutical R&D Processes
    by Michael M. Hopkins
  • 1999 Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
    by Ernst R. Berndt & Robert S. Pindyck & Pierre Azoulay
  • 1999 How to Win Schumpeterian Competition: Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Jochen Streb
  • 1999 How to Win Schumpeterian Competition: Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
    by Jochen Streb
  • 1999 Incidencia del régimen de patentes de la industria farmacéutica sobre la economía colombiana
    by Luis Alberto Zuleta Jaramillo & Mónica Lylián Parra Torrado
  • 1998 Demand for Prescription Drugs: The Effects of Managed Care Pharmacy Benefits
    by Rika Onishi Mortimer
  • 1998 Characterizing Informational Barriers To Entry In The Anti-Ulcer Drug Market
    by Matthew Shum
  • 1998 Random Coefficients and Unbalanced Panels: An Application on Data from Norwegian Chemical Plants
    by Erik Biørn & Kjersti-Gro Lindquist
  • 1998 The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?
    by Jean O. Lanjouw
  • 1998 The Impact of Generic Competition on Brand Name Market Shares - Evidence from Micro Data
    by Aronsson, Thomas & Bergman, Mats & Rudholm, Niklas
  • 1998 The Impact of Generic Competition on Brand Name Market Shares: Evidence from Micro Data
    by Aronsson, Thomas & Bergman, Mats A. & Rudholm, Niklas
  • 1998 Exploring the Persuasive Effects of a Commercial for a Pharamaceutical Product : The Elderly vs. Young Adults
    by Perrien, Jean & Roy, Jean & Guiot, Denis & Bastin, Etienne
  • 1998 Evolutionary innovations: learning, entrepreneurship and the dynamics of the firm
    by Maureen McKelvey
  • 1997 Foreign Direct Investment, Technological Capabilities and Performance in the Chinese Pharmaceutical Industry
    by Steven White & Hideki Yoshihara & Xielin Liu
  • 1997 Organizational Dynamics and Strcuture in the Chinese Pharmaceutical Industry: A Technological System Perspective
    by Steven White
  • 1997 Alternative Transition Trajectories for Complementary Asset Markets in China's Pharmaceutical Industry
    by Steven White & Xielin Liu
  • 1997 Outsourcing of Research by Pharmaceutical and Biotechnology Firms
    by Tapon, F. & Thong, M.
  • 1997 The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?
    by Lanjouw, J.O.
  • 1997 The Pharmaceutical Industry in India and Hungary. Policies, Institutions, and Technological Development
    by Felker, G. & Chaudhuri, S. & Gyorgy, K. & Goldman, M.
  • 1997 Medicinal Plants, Rescuing Global Heritage
    by Lambert, J. & Srivastava, J. & Vietmeyer, N.
  • 1997 Les prestataires logistiques et la distribution pharmaceutique. Les barrieres a l'entree: vitres blindees ou glaces sans tain
    by Mattiuzzo, N. & Le Goff, J.
  • 1997 Merger, Retionalisation and the "High Commitment" Organisation
    by Randle, K.
  • 1997 Israel: Secteur de l'equipement medical
    by Theriault, V.
  • 1997 Chili:Secteur de l'equipement medical
    by Froissart, S.
  • 1997 Belgique: Secteur de l'equipement medical haute technologie
    by Froissart, S.
  • 1997 Thailande: Secteur de l'equipement medical
    by Froissart, S.
  • 1997 Malaisie: Secteur de l'equipement medical de haute technologie
    by Froissart, S.
  • 1997 The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules
    by Fiona M. Scott Morton
  • 1997 Royalty rates, sub licensing considerations and joint ventures
    by Elli Malki
  • 1997 The economic sense of royalty rates
    by Elli Malki
  • 1997 Intellectual property and the valuation of biotechnology
    by Elli Malki
  • 1997 Entry Decisions in the Generic Pharmaceutical Industry
    by Fiona M. Scott Morton
  • 1997 The Objectives of the FDA's Office of Generic Drugs
    by Fiona Scott Morton
  • 1997 Economic consequences of the German environmental liability act: Capital market response for the chemical industry
    by Bartsch, Elga
  • 1996 Characteristics of Demand for Pharmaceutical Products : an Examination of four Cephalosporins
    by Ellison, S & Cockburn, I & Griliches, A & Hausman, J
  • 1996 Rewarding Failure: Performance Related Pay in a Pharmaceutical research and Development Company
    by Randle, K.
  • 1995 R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
    by Joseph A. Dimasi & Grabowski, Henry G. & Vernon, John
  • 1995 Genotyping by Combinatorial Optimization Techniques
    by Lancia, G.
  • 1995 Do Other Firms Matter in Oligopolies?
    by Haskel, Jonathan & Scaramozzino, Pasquale
  • 1995 The transmission of information in the transacting of primary products: the case of quality improvement in Thailand's natural rubber production
    by Shigetomi, Shinichi
  • 1994 Fast Growing Small Entrepreneurial Firms and their Venture Capital Backers: an Applied Principal-Agent Analysis
    by Gavin C Reid
  • 1994 The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry
    by Ernst R. Berndt & Linda Bui & David Reiley & Glen Urban
  • 1993 Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
    by Rebecca Henderson & Iain Cockburn
  • 1993 Generics and New Goods in Pharmaceutical Price Indexes
    by Zvi Griliches & Iain Cockburn
  • 1993 Pricing, Profits, and Technological Progress in the Pharmaceutical Industry
    by F. M. Scherer
  • Overseas Acquisition Versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
    by Jaya Prakash Pradhan & Abhinav Alakshendra
  • Global competitiveness of Indian Pharmaceutical Industry: Trends and Strategies
    by Jaya Prakash Pradhan
  • Direct-to-Consumer Advertising in Pharmaceutical Markets
    by Kurt R Brekke & Michael Kuhn